

Lonza L7™ hPSC Culture System for Research and Future Clinical Applications

By Ashish Mehta¹, Chrishan JA Ramachandra¹,
Glen L Sequiera¹, Scott D'Andrea², Amber Ellis²,
Winston Shim^{1,3}, ¹National Heart Research Institute
Singapore, Singapore; ²Lonza Walkersville, Inc.,
Walkersville, MD, USA; ³DUKE-NUS, Singapore

Introduction

Chemically defined and feeder-independent cell culture systems have provided a superior platform for reproducibility and standardization of human pluripotent stem cell (hPSC)-based research. As the field advances towards potential clinical applications involving hPSC-derived cell progenies, hPSC culture systems compliant with regulatory standards are necessary. Lonza has developed a robust xeno-free and defined system that could be translated for use in GMP and clinical-grade manufacturing. L7™ hPSC Culture System is a culture platform (medium, matrix, passaging solution and cryosolution) that supports every-other-day feeding of hPSCs. We evaluated Lonza L7™ hPSC Culture System for maintenance and expansion of human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs).

Methods

Human ESCs and hiPSCs¹ were maintained in L7™ hPSC Medium and passaged every 5–7 days using L7™ hPSC Passaging Solution. Dissociated hPSC colonies were seeded on L7™ hPSC Matrix. After four passages, molecular characterization for pluripotency was performed using immunostaining and FACS. The differentiation potential of hPSCs into three primary germ lineages was characterized through embryoid bodies (EBs)².

Advantages of L7™ hPSC Passaging Solution

1. Attachment ratio post-passaging is high (>90% cell aggregates attach in 16 hours)
2. High post-detachment viability (>90%)
3. Generates uniform-sized aggregates
4. Increased split ratios (1:8 to 1:10)

Results




Figure 1
(A) Schematic representation of dissociation protocol using L7™ hPSC Passaging Solution. (B) Phase contrast images showing stages of hPSC after addition of L7™ hPSC Passaging Solution for 5 minutes (I) note disruption of hPSC colonies (II) uniform small cell aggregates after Step 2 (III) and colonies after 16 hours of seeding on a fresh L7™ hPSC Matrix Coated Plate in L7™ hPSC Medium.




Figure 2
 (A) Graph shows the percentage attachment ratio of cell aggregates that attach at 16 hours post passing using various methods. Note the marked difference between the three methods. (B) Graph represents number of viable cells after 24 hours of passing with various methods. (C) Graph shows the total viable cells after 6 days of culture, comparing two different passing methods. Data presented are mean \pm s.e.m. of three experiments. Abbreviation: L7™ PS = L7™ hPSC Passing Solution.




Figure 3
 (A) Low magnification of hPSC culture on day 6, ready for passing. (B) Phase contrast image of an hPSC colony showing compactness. (C) Magnified phase contrast image of hPSCs maintained in L7™ hPSC Medium. Note hPSCs show high nucleus to cytoplasm ratio and are highly compact in morphology.




Figure 4
 (A) Immunostaining of hPSC colonies grown on L7™ hPSC Medium in combination with L7™ hPSC Matrix exhibiting pluripotency markers, Oct4, SSEA4, Tra-1-60 and Tra-1-81. Scale bar: 100 μ m. (B) Flow cytometric analyses demonstrate more than 85% cells express pluripotency markers. A total of 10,000 events were counted and evaluated.




Figure 5
(A) Phase contrast image of 5-day-old EBs showing ability of hPSCs grown in L7™ hPSC Culture System for differentiation. (B) Semi-quantitative RT-PCR for two lines showing the ability of the cells to differentiate into three germ layers, ectoderm (Nestin-lane 5, 6; Pax6-lane 7, 8), mesoderm (GATA4-lane 9, 10; Isl1-lane 11, 12) and endoderm (AFP-lane 13, 14; HNF4α-lane 15, 16), with GAPDH (lane 3, 4) as housekeeping gene. hiPSC line (lane 3, 5, 7, 9, 11, 13, 15) and hESC line (lane 4, 6, 8, 10, 12, 14, 16). Molecular weight ladder (lane 1, 18)

Conclusion

We evaluated L7™ hPSC Culture System to passage 4 and found it to be a robust and efficient system for expansion and growth of hPSCs in a xeno-free, regulatory-compliant environment for use in both research and clinical applications involving hPSC-derived cell derivatives. For long-term data, please see ISSCR poster # T-2173, “Robust Generation and Maintenance of Human Induced Pluripotent Stem Cells Under Defined Conditions”.

References

1. Mehta A et al., *Cardiovasc Res.* 2011; 91: 577–586.
2. Mehta A et al., *Toxicol Sci.* 2013; 131: 458–469.

Acknowledgements

A.M., W.S., C.R., G.S., are funded by the National Research Foundation Singapore (NRF-CRP-2008-02), National Medical Research Council (NMRC/BNIG/1074/2012), Goh Foundation Gift (Singapore)/Duke-NUS Graduate Medical School (GCR/2013/0008 and GCR/2013/011) and Biomedical Research Council Singapore (BMRC 13/1/96/686).

Contact Information

North America

Customer Service: +1 800 638 8174 (toll free)
order.us@lonza.com
Scientific Support: +1 800 521 0390 (toll free)
scientific.support@lonza.com

Europe

Customer Service: +32 87 321 611
order.europe@lonza.com
Scientific Support: +32 87 321 611
scientific.support.eu@lonza.com

International

Contact your local Lonza distributor
Customer Service: +1 301 898 7025
Fax: +1 301 845 8291
scientific.support@lonza.com

Lonza Cologne GmbH – 50829 Cologne Germany

Unless otherwise noted, all trademarks herein are marks of the Lonza Group Ltd or its affiliates. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights.